Publicacións en colaboración con investigadores/as de Instituto de Investigación Sanitaria Biocruces Bizkaia (31)

2024

  1. Serum and Urine Metabolomic Profiling of Newly Diagnosed Treatment-Naïve Inflammatory Bowel Disease Patients

    Inflammatory Bowel Diseases, Vol. 30, Núm. 2, pp. 167-182

  2. The biochemical pattern defines MASLD phenotypes linked to distinct histology and prognosis

    Journal of Gastroenterology

2023

  1. Long-Term Outcomes of Biological Therapy in Crohn's Disease Complicated with Internal Fistulizing Disease: BIOSCOPE Study from GETECCU

    American Journal of Gastroenterology, Vol. 118, Núm. 6, pp. 1036-1046

  2. Recent Advances and Potential Multi-Omics Approaches in the Early Phases of Inflammatory Bowel Disease

    Journal of Clinical Medicine, Vol. 12, Núm. 10

  3. Surfing the web as a patient with IBD: New horizons

    United European Gastroenterology Journal

2022

  1. Corrigendum to: Re-induction With Intravenous Ustekinumab in Patients With Crohn's Disease and a Loss of Response to This Therapy

    Inflammatory bowel diseases

  2. Erratum: Re-induction with Intravenous Ustekinumab in Patients with Crohn's Disease and a Loss of Response to This Therapy (Inflammatory Bowel Diseases DOI: 10.1093/ibd/izab015)

    Inflammatory Bowel Diseases

  3. Management and Long-term Outcomes of Crohn's Disease Complicated with Enterocutaneous Fistula: ECUFIT Study from GETECCU

    Journal of Crohn's & colitis, Vol. 16, Núm. 7, pp. 1049-1058

  4. Mild to moderate ulcerative colitis: Call me by my name

    United European Gastroenterology Journal

  5. Nationwide COVID-19-EII Study: Incidence, Environmental Risk Factors and Long-Term Follow-Up of Patients with Inflammatory Bowel Disease and COVID-19 of the ENEIDA Registry

    Journal of Clinical Medicine, Vol. 11, Núm. 2

  6. Re-induction With Intravenous Ustekinumab in Patients With Crohn's Disease and a Loss of Response to This Therapy

    Inflammatory bowel diseases, Vol. 28, Núm. 1, pp. 41-47

  7. Risk Factors for COVID-19 in Inflammatory Bowel Disease: A National, ENEIDA-Based Case–Control Study (COVID-19-EII)

    Journal of Clinical Medicine, Vol. 11, Núm. 24

  8. SARS-CoV-2 vaccine acceptance among gastroenterologists and inflammatory bowel disease patients: VACUNEII project

    Gastroenterologia y Hepatologia, Vol. 45, Núm. 10, pp. 737-741

  9. Synergism interaction between genetic polymorphisms in drug metabolizing enzymes and NSAIDs on upper gastrointestinal haemorrhage: a multicenter case-control study

    Annals of medicine, Vol. 54, Núm. 1, pp. 379-392

2021

  1. A multicenter case–control study of the effect of e-nos VNTR polymorphism on upper gastrointestinal hemorrhage in NSAID users

    Scientific Reports, Vol. 11, Núm. 1

  2. Corrigendum to “Recomendaciones del Grupo Español de Trabajo en enfermedad de Crohn y colitis ulcerosa (GETECCU) sobre la reservoritis en la colitis ulcerosa. Parte 2: Tratamiento” [Gastroenterología y Hepatología 2020;43(10):649-658](S0210570520301606)(10.1016/j.gastrohep.2020.04.004)

    Gastroenterologia y Hepatologia

  3. Epidemiological pattern, incidence, and outcomes of COVID-19 in liver transplant patients

    Journal of Hepatology, Vol. 74, Núm. 1, pp. 148-155

  4. Polyprev: Randomized, multicenter, controlled trial comparing fecal immunochemical test with endoscopic surveillance after advanced adenoma resection in colorectal cancer screening programs: A study protocol

    Diagnostics, Vol. 11, Núm. 9

  5. Preclinical Inflammatory Bowel Disease: Back to the Future

    Gastroenterology

  6. The natural history of extraintestinal manifestations after surgery in inflammatory bowel disease: Never give up!

    United European Gastroenterology Journal